vs
Emergent BioSolutions Inc.（EBS）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
LiveRamp Holdings, Inc.的季度营收约是Emergent BioSolutions Inc.的1.4倍（$212.2M vs $148.7M），LiveRamp Holdings, Inc.净利率更高（18.8% vs -36.7%，领先55.5%），LiveRamp Holdings, Inc.同比增速更快（8.6% vs -23.6%），过去两年LiveRamp Holdings, Inc.的营收复合增速更高（11.1% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
EBS vs RAMP — 直观对比
营收规模更大
RAMP
是对方的1.4倍
$148.7M
营收增速更快
RAMP
高出32.2%
-23.6%
净利率更高
RAMP
高出55.5%
-36.7%
两年增速更快
RAMP
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $212.2M |
| 净利润 | $-54.6M | $39.9M |
| 毛利率 | 42.9% | 71.9% |
| 营业利润率 | -18.8% | 18.6% |
| 净利率 | -36.7% | 18.8% |
| 营收同比 | -23.6% | 8.6% |
| 净利润同比 | -74.4% | 255.7% |
| 每股收益（稀释后） | $-0.95 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSRAMP
| Q4 25 | $148.7M | $212.2M | ||
| Q3 25 | $231.1M | $199.8M | ||
| Q2 25 | $140.9M | $194.8M | ||
| Q1 25 | $222.2M | $188.7M | ||
| Q4 24 | $194.7M | $195.4M | ||
| Q3 24 | $293.8M | $185.5M | ||
| Q2 24 | $254.7M | $176.0M | ||
| Q1 24 | $300.4M | $171.9M |
净利润EBSRAMP
| Q4 25 | $-54.6M | $39.9M | ||
| Q3 25 | $51.2M | $27.4M | ||
| Q2 25 | $-12.0M | $7.7M | ||
| Q1 25 | $68.0M | $-6.3M | ||
| Q4 24 | $-31.3M | $11.2M | ||
| Q3 24 | $114.8M | $1.7M | ||
| Q2 24 | $-283.1M | $-7.5M | ||
| Q1 24 | $9.0M | $-5.4M |
毛利率EBSRAMP
| Q4 25 | 42.9% | 71.9% | ||
| Q3 25 | 62.8% | 70.2% | ||
| Q2 25 | 52.5% | 70.1% | ||
| Q1 25 | 60.2% | 69.3% | ||
| Q4 24 | 39.4% | 71.9% | ||
| Q3 24 | 54.9% | 72.4% | ||
| Q2 24 | -18.8% | 70.6% | ||
| Q1 24 | 49.2% | 72.2% |
营业利润率EBSRAMP
| Q4 25 | -18.8% | 18.6% | ||
| Q3 25 | 33.1% | 10.7% | ||
| Q2 25 | 1.1% | 3.7% | ||
| Q1 25 | 22.5% | -6.1% | ||
| Q4 24 | -4.9% | 7.5% | ||
| Q3 24 | 22.0% | 4.0% | ||
| Q2 24 | -79.9% | -3.0% | ||
| Q1 24 | 13.2% | -8.3% |
净利率EBSRAMP
| Q4 25 | -36.7% | 18.8% | ||
| Q3 25 | 22.2% | 13.7% | ||
| Q2 25 | -8.5% | 4.0% | ||
| Q1 25 | 30.6% | -3.3% | ||
| Q4 24 | -16.1% | 5.7% | ||
| Q3 24 | 39.1% | 0.9% | ||
| Q2 24 | -111.2% | -4.3% | ||
| Q1 24 | 3.0% | -3.1% |
每股收益（稀释后）EBSRAMP
| Q4 25 | $-0.95 | $0.62 | ||
| Q3 25 | $0.91 | $0.42 | ||
| Q2 25 | $-0.22 | $0.12 | ||
| Q1 25 | $1.19 | $-0.10 | ||
| Q4 24 | $-0.45 | $0.17 | ||
| Q3 24 | $2.06 | $0.03 | ||
| Q2 24 | $-5.38 | $-0.11 | ||
| Q1 24 | $0.17 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $403.4M |
| 总债务越低越好 | $589.7M | — |
| 股东权益账面价值 | $522.6M | $962.3M |
| 总资产 | $1.3B | $1.3B |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资EBSRAMP
| Q4 25 | $205.4M | $403.4M | ||
| Q3 25 | $245.5M | $376.9M | ||
| Q2 25 | $267.3M | $371.1M | ||
| Q1 25 | $149.1M | $420.8M | ||
| Q4 24 | $99.5M | $384.3M | ||
| Q3 24 | $149.9M | $348.4M | ||
| Q2 24 | $69.7M | $342.7M | ||
| Q1 24 | $78.5M | $368.9M |
总债务EBSRAMP
| Q4 25 | $589.7M | — | ||
| Q3 25 | $693.1M | — | ||
| Q2 25 | $700.0M | — | ||
| Q1 25 | $700.0M | — | ||
| Q4 24 | $700.0M | — | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — | ||
| Q1 24 | $909.2M | — |
股东权益EBSRAMP
| Q4 25 | $522.6M | $962.3M | ||
| Q3 25 | $582.5M | $943.8M | ||
| Q2 25 | $536.2M | $947.8M | ||
| Q1 25 | $552.7M | $948.9M | ||
| Q4 24 | $482.8M | $957.7M | ||
| Q3 24 | $508.4M | $932.1M | ||
| Q2 24 | $386.3M | $951.9M | ||
| Q1 24 | $663.9M | $949.1M |
总资产EBSRAMP
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.4B | $1.2B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.8B | $1.2B |
负债/权益比EBSRAMP
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — | ||
| Q1 24 | 1.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | — |
| 自由现金流经营现金流 - 资本支出 | $73.8M | — |
| 自由现金流率自由现金流/营收 | 49.6% | — |
| 资本支出强度资本支出/营收 | 2.6% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $156.8M | — |
8季度趋势，按日历期对齐
经营现金流EBSRAMP
| Q4 25 | $77.7M | — | ||
| Q3 25 | $-2.3M | $57.4M | ||
| Q2 25 | $106.4M | $-15.8M | ||
| Q1 25 | $-11.2M | — | ||
| Q4 24 | $-79.9M | $45.1M | ||
| Q3 24 | $153.7M | $55.6M | ||
| Q2 24 | $47.5M | $-9.3M | ||
| Q1 24 | $-62.6M | — |
自由现金流EBSRAMP
| Q4 25 | $73.8M | — | ||
| Q3 25 | $-5.7M | $56.8M | ||
| Q2 25 | $103.5M | $-16.2M | ||
| Q1 25 | $-14.8M | — | ||
| Q4 24 | $-81.6M | $44.8M | ||
| Q3 24 | $147.9M | $55.4M | ||
| Q2 24 | $42.9M | $-9.6M | ||
| Q1 24 | $-73.4M | — |
自由现金流率EBSRAMP
| Q4 25 | 49.6% | — | ||
| Q3 25 | -2.5% | 28.4% | ||
| Q2 25 | 73.5% | -8.3% | ||
| Q1 25 | -6.7% | — | ||
| Q4 24 | -41.9% | 22.9% | ||
| Q3 24 | 50.3% | 29.8% | ||
| Q2 24 | 16.8% | -5.4% | ||
| Q1 24 | -24.4% | — |
资本支出强度EBSRAMP
| Q4 25 | 2.6% | 0.1% | ||
| Q3 25 | 1.5% | 0.3% | ||
| Q2 25 | 2.1% | 0.2% | ||
| Q1 25 | 1.6% | 0.2% | ||
| Q4 24 | 0.9% | 0.1% | ||
| Q3 24 | 2.0% | 0.1% | ||
| Q2 24 | 1.8% | 0.1% | ||
| Q1 24 | 3.6% | 1.0% |
现金转化率EBSRAMP
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | 1.34× | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | -6.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RAMP
暂无分部数据
